Raymond James Financial
SPRO icon

Raymond James Financial’s Spero Therapeutics SPRO Stock Holding History

Raymond James Financial’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,082
Closed -$8.94K – 6521
2025
Q2 		$8.94K Buy
+3,082
New +$4.43K ﹤0.01% 5966

Other funds holding SPRO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial's SPRO Position: Q3 2025 in Review

Raymond James Financial sold out of Spero Therapeutics (SPRO) in Q3 2025, closing a stake of 3,082 shares — an estimated $8.94K sold.

Raymond James Financial first reported a position in SPRO in Q2 2025 and held it in 1 quarter. The position peaked at $8.94K in Q2 2025. 47 funds tracked by Wall St. Rank hold SPRO as of Q3 2025.

  • Raymond James Financial reported no remaining Spero Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 3,082 Spero Therapeutics shares in Q3 2025, an estimated $8.94K.
  • Raymond James Financial first reported a position in Spero Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Spero Therapeutics position peaked at $8.94K in Q2 2025.
  • 47 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.